Short Interest in Gyrodyne Drops by Over a Third

Gyrodyne's stock sees significant decrease in short positions as institutional investors increase holdings.

Mar. 29, 2026 at 1:06am

Got story updates? Submit your updates here. ›

An extreme close-up of interlocking metal gears, levers, and mechanical components in muted industrial tones, conceptually representing the complex financial infrastructure supporting Gyrodyne's medical office real estate business.The inner workings of Gyrodyne's specialized medical office real estate portfolio reveal the complex financial machinery powering the company's steady growth.Stony Brook Today

Gyrodyne, LLC (NASDAQ:GYRO), a New York-based real estate investment and development firm focused on medical office buildings, saw a 37.5% decrease in short interest in March. As of March 13th, there were only 45 shares shorted, down from 72 shares at the end of February. Institutional investors have been increasing their positions in Gyrodyne, with several firms adding the stock to their portfolios in the third quarter of the previous year.

Why it matters

The drop in short interest suggests growing investor confidence in Gyrodyne's business model and future prospects. As a niche player in the medical office space, Gyrodyne's performance is seen as a bellwether for the broader healthcare real estate sector.

The details

Gyrodyne's stock price has fluctuated between $6.80 and $12.00 over the past 52 weeks, with the company's average daily trading volume around 798 shares. The short interest ratio, which measures the number of days it would take to cover all the short positions, has fallen to just 0.1 days.

  • As of March 13th, 2026, Gyrodyne had 45 shares shorted.
  • On February 26th, 2026, Gyrodyne had 72 shares shorted.

The players

Gyrodyne, LLC

A New York-based real estate investment and development firm that specializes in medical office buildings and professional facilities.

Advisory Services Network LLC

An institutional investor that purchased a new stake in Gyrodyne during the 3rd quarter of the previous year.

Susquehanna International Group LLP

An institutional investor that purchased a new position in Gyrodyne in the 3rd quarter of the previous year.

Teton Advisors LLC

An institutional investor that purchased a new stake in Gyrodyne during the 3rd quarter of the previous year, valued at approximately $177,000.

Bulldog Investors LLP

An institutional investor that purchased a new stake in Gyrodyne during the 3rd quarter of the previous year, valued at approximately $601,000.

Got photos? Submit your photos here. ›

The takeaway

The significant drop in short interest for Gyrodyne's stock suggests that institutional investors see value in the company's focus on the medical office real estate market. As healthcare real estate continues to be an attractive sector, Gyrodyne's performance could be an indicator of broader trends in the industry.